Cipla unveils drone based delivery for essential medicines for hospitals, pharmacies in Himachal Pradesh
Mumbai: Cipla Limited has announced the launch of drone-powered deliveries for its critical medicines (cardiac, respiratory and other essential chronic therapies) for hospitals and pharmacies in Himachal Pradesh, India, in partnership with Skye Air Mobility. The use of drones will support on-time delivery of Cipla’s medicines to chemists and clinics in remote areas, while minimizing risks such as delays, temperature excursions affecting cold chain products, and roadside accidents. "Cipla is the first among large Indian pharma companies to adopt drone-based deliveries to facilitate expedited supply to stockists in remote areas," the Company claimed .
In its inaugural phase, the company has successfully completed several drone deliveries in Himachal Pradesh covering approximately 50 kilometres distance in under 25 minutes. This has been vital amidst adverse and prevailing weather conditions that have impacted conventional transportation routes in the state.
Commenting on the milestone, Cipla’s Global Supply Chain Head, Swapn Malpani said, “Driven by our purpose of ‘Caring for Life’, we are leveraging technology to make healthcare more accessible and extend our circle of care to all our key stakeholders. As we accelerate our digital agenda across all functions, implementing drone-powered distribution enhances our supply chain resilience, strengthens connects with channel partners, helps us stay future ready and maintain reliable, prompt delivery of our trusted high-quality drugs to stockists and patients in the region."
Cipla aims to scale the service in the future through distribution to hospitals and expand market coverage to inaccessible and hilly terrains such as Uttarakhand and Northeast in India.
Cipla Limited is an Indian multinational pharmaceutical and biotechnology company headquartered in Mumbai, India. Khwaja Abdul Hamied founded the Company in 1935 in Mumbai.
The Company specializes in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments. Cipla's 47 manufacturing sites worldwide produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to 86 markets.
